利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

493 条记录 (耗时 0.042 秒)

    METHOD OF TREATING DISORDERS OF THE CARDIOVASCULAR SYSTEM AND A PHARMACEUTICAL AGENT
    18.
    发明申请
    METHOD OF TREATING DISORDERS OF THE CARDIOVASCULAR SYSTEM AND A PHARMACEUTICAL AGENT 审中-公开
    治疗心血管系统疾病和药物代谢的方法

    公开(公告)号：US20160184256A1

    公开(公告)日：2016-06-30

    申请号：US15059226

    申请日：2016-03-02

    申请人： Oleg Iliich Epshtein

    发明人： Oleg Iliich Epshtein

    IPC分类号： A61K31/277

    CPC分类号： C07K16/44 ,  A61K31/277 ,  A61K39/39583 ,  A61K41/0004 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/00 ,  C07K16/22 ,  C07K16/24 ,  C07K16/241 ,  C07K16/243 ,  C07K16/245 ,  C07K16/246 ,  C07K16/248 ,  C07K16/249 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2806 ,  C07K16/40 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/77

    摘要： A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome.Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

    摘要翻译： 治疗病理综合征的方法包括向抗原施用超低剂量抗体的活化形式，其中所述活化形式通过反复连续稀释与外部冲击结合获得，并且所述抗原是施用的物质或药剂 影响这种特殊病理综合征的形成机制。 用于治疗病理综合征的药物包含针对抗原的超低剂量的单克隆抗体，多克隆抗体或天然抗体的活化形式，其中所述活化形式通过重复连续稀释和外部治疗（主要基于顺势疗法技术）制备，所述 抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。 在此情况下，针对自身抗原，胎儿抗原，针对外源性或内源性抗原产生超低剂量抗体的活化形式; 也使用抗独特型抗体。

    ENHANCED ANABOLIC CYTOKINE PRODUCTION AND DELIVERY SYSTEM
    19.
    发明申请
    ENHANCED ANABOLIC CYTOKINE PRODUCTION AND DELIVERY SYSTEM 审中-公开
    增强免疫细胞生产和输送系统

    公开(公告)号：US20160101132A1

    公开(公告)日：2016-04-14

    申请号：US14970574

    申请日：2015-12-16

    申请人： ARTHREX, INC.

    发明人： Christopher M. Bare ,  Brandon L. Roller ,  Melissa S. Tucker

    IPC分类号： A61K35/16 ,  A61M1/36 ,  C07K16/24

    CPC分类号： A61K35/16 ,  A61J1/2089 ,  A61K38/1793 ,  A61M1/362 ,  C07K16/245

    摘要： Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1β, IL-α, IL-6, TNFα, IFNγ and MMPS as these proteins inhibit the healing process.

    摘要翻译： 从含有这种不想要的/抑制成分的组合物（例如，自体流体或血清）中去除（过滤掉）不想要的/抑制成分（例如，产物，副产物和/或细胞输出如抑制性分解代谢蛋白）的技术和装置。 所述装置包括设计成含有含有抑制/不需要的成分（产物，副产物和/或细胞的输出例如抑制性分解代谢蛋白）的组合物（例如自体流体或血清）的至少一种构建体。 该构建体设置有内壁，其包括设计成从组合物中除去抑制/不想要的组分（例如，特定蛋白质）的特异性蛋白质捕获装置。 靶向捕获的蛋白质包括但不限于分解代谢细胞因子如IL-1和bgr; IL-α，IL-6，TNFα，IFNγ和MMPS，因为这些蛋白质抑制愈合过程。